Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $12 to $6.
Needham Maintains Buy on NextCure, Lowers Price Target to $6
Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $12 to $6.
Related Posts
What’s Going On With Alibaba Shares
Alibaba Group Holding Ltd - ADR (NYSE: BABA) shares are trading lower by 1.4% to $85.00 Thursday morning on recent, continued weakness.
Ethereum (ETH) Miners Won’t Find Much Revenue On Ethereum Classic (ETC): CoinMetrics
Ethereum (CRYPTO: ETH) miners that have migrated to the Ethereum Classic (CRYPTO: ETC) chain are making a small fraction of the daily revenue they used to make on ETH pre-Merge, according to bloc
Deep Medicine Acquisition Corp. Announces Listing Transfer To The Nasdaq Capital Market
Deep Medicine Acquisition Corp. (NASDAQ:DMAQ) (the "Company") announced today that it has received approval from the Nasdaq Stock Market ("Nasdaq") to transfer the listing of its securities from the